keyword
MENU ▼
Read by QxMD icon Read
search

renal carcinoma

keyword
https://www.readbyqxmd.com/read/29667779/mir-193a-3p-and-mir-224-mediate-renal-cell-carcinoma-progression-by-targeting-alpha-2-3-sialyltransferase-iv-and-the-phosphatidylinositol-3-kinase-akt-pathway
#1
Yue Pan, Jialei Hu, Jia Ma, Xia Qi, Huimin Zhou, Xiaoyan Miao, Wei Zheng, Li Jia
Tumor metastasis is a major cause of cancer-related death in renal cell carcinoma (RCC). MicroRNAs (miRNAs) have been widely known to modulate proliferation invasion, metastasis and apoptosis of cancer cells. In this study, we aimed to investigate the function and novel target of miR-193a-3p and miR-224 in RCC. The levels of miR-193a-3p and miR-224 were significantly increased in RCC tissues and RCC cell lines. Alpha-2, 3-Sialyltransferase IV (ST3GalIV) was highly expressed in adjacent nontumor tissues and human normal proximal tubular cell line HK-2 compared to RCC tissues and cell lines...
April 18, 2018: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/29667067/a-first-in-class-inhibitor-mln4924-pevonedistat-induces-cell-cycle-arrest-senescence-and-apoptosis-in-human-renal-cell-carcinoma-by-suppressing-ube2m-dependent-neddylation-modification
#2
Bo Xu, Yuyou Deng, Ran Bi, Haoran Guo, Chang Shu, Neelam Kumari Shah, Junliang Chang, Guanchen Liu, Yujun Du, Wei Wei, Chunxi Wang
PURPOSE: MLN4924 is a second-generation inhibitor that targets ubiquitin-proteasome system by inhibiting neddylation activation enzyme (NAE), and subsequently blocking the neddylation-dependent activation of Cullin-RING E3 ligases (CRLs), which leads to the accumulation of CRLs substrates and hence, suppressing diverse tumor development. In this study, we investigated the potential application of this first-in-class inhibitor MLN4924 in the treatment of human renal cell carcinoma both in vitro and in vivo...
April 17, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29667066/population-exposure-response-analysis-of-cabozantinib-efficacy-and-safety-endpoints-in-patients-with-renal-cell-carcinoma
#3
Steven Lacy, Jace Nielsen, Bei Yang, Dale Miles, Linh Nguyen, Matt Hutmacher
BACKGROUND: In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy. In METEOR, RCC patients started at a daily 60-mg cabozantinib tablet (Cabometyx™) dose but could reduce to 40- or 20-mg to achieve a tolerated exposure. OBJECTIVES AND METHODS: Exposure-response (ER) models were developed to characterize the relationship between cabozantinib at clinically relevant exposures in RCC patients enrolled in METEOR and efficacy (PFS and tumor response) and safety endpoints...
April 17, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29666728/a-rare-benign-tumor-in-a-14-year-old-girl
#4
Meral Hassan Abualjadayel, Osama Y Safdar, Maysaa Adnan Banjari, Sherif El Desoky, Ghadeer A Mokhtar, Raed A Azhar
Background: Oncocytomas are the second most common benign renal neoplasm but, unfortunately, they are difficult to differentiate from renal cell carcinoma. Renal oncocytomas are rare and have mostly been reported in adults. To our knowledge, this is only the sixth pediatric reported case of renal oncocytoma worldwide. Case Presentation: A 14-year-old Yemeni girl with a recurrent history of urinary tract infections came to our clinic complaining of left flank pain with a frontal headache...
2018: Case Reports in Nephrology
https://www.readbyqxmd.com/read/29665787/valproic-acid-sensitizes-metformin-resistant-human-renal-cell-carcinoma-cells-by-upregulating-h3-acetylation-and-emt-reversal
#5
Muyun Wei, Shaowei Mao, Guoliang Lu, Liang Li, Xiaopeng Lan, Zhongxian Huang, Yougen Chen, Miaoqing Zhao, Yueran Zhao, Qinghua Xia
BACKGROUND: Metformin (Met) is a widely available diabetic drug and shows suppressed effects on renal cell carcinoma (RCC) metabolism and proliferation. Laboratory studies in RCC suggested that metformin has remarkable antitumor activities and seems to be a potential antitumor drug. But the facts that metformin may be not effective in reducing the risk of RCC in cancer clinical trials made it difficult to determine the benefits of metformin in RCC prevention and treatment. The mechanisms underlying the different conclusions between laboratory experiments and clinical analysis remains unclear...
April 17, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29665739/pax8-positive-b-cell-lymphoma-in-adrenal-gland-masquerading-as-metastatic-renal-cell-carcinoma
#6
Rugvedita Parakh, Lin Cheng, Maria Tretiakova
Extranodal lymphomas involve adrenal glands as a mass lesion in 3% to 5% of cases as identified by imaging studies. Definitive diagnosis of the neoplasm is provided by morphological and immunophenotypical evaluation on limited tissue obtained by fine needle aspiration or core biopsy. We report a diagnostically challenging case that presented as masses involving adrenal gland and lung in the setting of a concurrent primary renal cell carcinoma. PAX8, a frequently used marker for renal cell carcinoma, was immunoreactive in the neoplastic cells of the adrenal mass, and thus highly suggestive for metastatic renal cell carcinoma...
April 1, 2018: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29665666/-early-results-of-fenestrated-endovascular-aortic-repair-for-the-treatment-of-patients-with-thoracoabdominal-pathologies
#7
J C Zhu, X C Dai, Y D Luo, H L Fan, Z Feng, Y W Zhang, F G Hu
Objective: To evaluate the early results of fenestrated endovascular aortic repair (FEVAR) using physician-modified stent grafts (PMSGs) for the treatment of patients with thoracoabdominal pathologies. Methods: Nineteen consecutive patients who underwent FEVAR using PMSGs between April 2012 and September 2017 were retrospectively reviewed. The modality of FEVAR technique was assessed, perioperative clinical data was recorded and the early results were evaluated. Results: Indications were thoracoabdominal aortic pathologies, including juxtarenal abdominal aortic aneurysm (JAAA) ( n =12), chronic thoracoabdominal aortic dissection with aneurysmal dilatation ( n =3), thoracoabdominal aortic aneurysm (TAAA) ( n =1), infrarenal AAA with an accessory renal artery in the segment of the aneurysmal neck ( n =2) and type Ⅰ endoleak after EVAR for AAA( n =1)...
March 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29665588/current-technique-and-application-of-percutaneous-cryotherapy
#8
Andreas H Mahnken, Alexander Marc König, Jens Holger Figiel
PURPOSE:  Local ablative therapies have become an established treatment option in interventional oncology. Radiofrequency ablation (RFA) and microwave ablation (MWA) are a standard of care in the treatment of hepatocellular carcinoma (HCC). Currently, there is an increasing interest in cryotherapy, one of the oldest ablation techniques. It has some unique characteristics with regard to technology and mechanism of action. MATERIALS AND METHODS:  A systematic literature search using the terms cryotherapy, cryosurgery and cryoablation was performed...
April 17, 2018: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
https://www.readbyqxmd.com/read/29665322/tumour-cell-expression-of-interleukin-6-receptor-%C3%AE-is-associated-with-response-rates-in-patients-treated-with-sunitinib-for-metastatic-clear-cell-renal-cell-carcinoma
#9
Martin Pilskog, Leif Bostad, Reidunn J Edelmann, Lars A Akslen, Christian Beisland, Oddbjørn Straume
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and anti-angiogenic treatment is currently first line therapy for metastatic ccRCC (mccRCC). Response rates and duration of response show considerable variation, and adverse events have a major influence on patient quality of life. The need for predictive biomarkers to select responders to receptor tyrosine kinase inhibitors upfront is urgent. We investigated the predictive value of immunohistochemical biomarkers associated with angiogenesis and systemic inflammation in mccRCC...
April 2018: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/29665139/high-grade-infiltrative-adenocarcinomas-of-renal-cell-origin-new-insights-into-classification-morphology-and-molecular-pathogenesis
#10
REVIEW
Jaime A Singh, Chisato Ohe, Steven Christopher Smith
Collecting duct carcinoma was described over 30 years ago as a renal tumor, based in the medullary collecting system, with tubulopapillary morphology, prominent infiltrative growth, and stromal desmoplasia. While diagnostic workup has always emphasized exclusion of upper tract urothelial carcinoma and metastatic adenocarcinoma to the kidney, the molecular era of renal cell carcinoma classification has enabled recognition of and provided tools for diagnosis of new entities in this morphologic differential. In this review, we consider these developments, with emphasis on renal medullary carcinoma, closely related renal cell carcinoma, unclassified with medullary phenotype, and fumarate hydratase-deficient renal cell carcinoma...
April 17, 2018: Pathology International
https://www.readbyqxmd.com/read/29664405/longitudinal-assessment-of-vascular-function-with-sunitinib-in-patients-with-metastatic-renal-cell-carcinoma
#11
Anna B Catino, Rebecca A Hubbard, Julio A Chirinos, Ray Townsend, Stephen Keefe, Naomi B Haas, Igor Puzanov, James C Fang, Neeraj Agarwal, David Hyman, Amanda M Smith, Mary Gordon, Theodore Plappert, Virginia Englefield, Vivek Narayan, Steven Ewer, Chantal ElAmm, Daniel Lenihan, Bonnie Ky
BACKGROUND: Sunitinib, used widely in metastatic renal cell carcinoma, can result in hypertension, left ventricular dysfunction, and heart failure. However, the relationships between vascular function and cardiac dysfunction with sunitinib are poorly understood. METHODS AND RESULTS: In a multicenter prospective study of 84 metastatic renal cell carcinoma patients, echocardiography, arterial tonometry, and BNP (B-type natriuretic peptide) measures were performed at baseline and at 3...
March 2018: Circulation. Heart Failure
https://www.readbyqxmd.com/read/29663528/purely-off-clamp-robotic-partial-nephrectomy-preliminary-3-year-oncological-and-functional-outcomes
#12
Giuseppe Simone, Leonardo Misuraca, Gabriele Tuderti, Francesco Minisola, Mariaconsiglia Ferriero, Giuseppe Romeo, Manuela Costantini, Samer F Al-Rawashdah, Salvatore Guaglianone, Michele Gallucci
OBJECTIVES: To describe our surgical technique and to report perioperative, 3-year oncological and functional outcomes of a single-center series of purely off-clamp robotic partial nephrectomy. METHODS: A prospective renal cancer institutional database was queried, and data of consecutive patients treated with purely off-clamp robotic partial nephrectomy between 2010 and 2015 in a high-volume center were collected. Perioperative complications, and 3-year oncological and functional outcomes were assessed...
April 16, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29663063/-treatment-with-pd-1-pd-l1-and-ctla-4-immune-checkpoint-inhibitors-immune-mediated-side-effects
#13
REVIEW
M-O Grimm, H Oppel-Heuchel, S Foller
Immune checkpoint inhibitors are a new standard therapy for advanced or metastatic urothelial as well as renal cell carcinoma. Atezolizumab and Pembrolizumab have been approved for the treatment of cisplatin-ineligible patients with transitional call cancer in the 1st line setting; both antibodies and Nivolumab may also be used after platinum based prior therapy. Regarding renal cell carcinoma approval for 1st line treatment with the combination of Nivolumab and Ipilimumab for patients at intermediate or high risk (IMDC) is currently expected...
April 16, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29662856/renal-cell-carcinoma-metastasizing-to-the-myeloproliferative-bone-marrow
#14
Thein Hlaing Oo, Roberto Nicolas Miranda
No abstract text is available yet for this article.
March 2018: Blood Research
https://www.readbyqxmd.com/read/29662646/vhl-status-regulates-transforming-growth-factor-%C3%AE-signaling-pathways-in-renal-cell-carcinoma
#15
Pramod Mallikarjuna, Raviprakash T Sitaram, Maréne Landström, Börje Ljungberg
To evaluate the role of pVHL in the regulation of TGF-β signaling pathways in clear cell renal cell carcinoma (ccRCC) as well as in non-ccRCC; the expression of pVHL, and the TGF-β pathway components and their association with clinicopathological parameters and patient's survival were explored. Tissue samples from 143 ccRCC and 58 non-ccRCC patients were examined by immunoblot. ccRCC cell lines were utilized for mechanistic in-vitro studies. Expression levels of pVHL were significantly lower in ccRCC compared with non-ccRCC...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662642/successful-retreatment-with-grazoprevir-and-elbasvir-for-patients-infected-with-hepatitis-c-virus-genotype-1b-who-discontinued-prior-treatment-with-ns5a-inhibitor-including-regimens-due-to-adverse-events
#16
Tatsuo Kanda, Shin Yasui, Masato Nakamura, Shingo Nakamoto, Koji Takahashi, Shuang Wu, Reina Sasaki, Yuki Haga, Sadahisa Ogasawara, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Yoshihiko Ooka, Eiichiro Suzuki, Tetsuhiro Chiba, Hitoshi Maruyama, Mitsuhiko Moriyama, Naoya Kato
Background: Sustained virologic response (SVR) by interferon and interferon-free treatment can results in the reduction of advanced liver fibrosis and the occurrence of hepatocellular carcinoma in patients infected with hepatitis C virus (HCV). Recent interferon-free treatment for HCV shortens the duration of treatment and leads to higher SVR rates, without any serious adverse events. However, it is important to retreat patients who have had treatment-failure with HCV non-structural protein 5A (NS5A) inhibitor-including regimens...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662544/sunitinib-in-the-treatment-of-renal-cell-carcinoma-an-update-on-recent-evidence
#17
REVIEW
Mimma Rizzo, Camillo Porta
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in January 2006, sunitinib represents a key molecule in the treatment of metastatic renal cell carcinoma (mRCC) due to the peculiar molecular pathogenesis of this neoplasm. Over the past 10 years, clinical trials and real-world experiences helped clinicians to understand how, when and for how long to use sunitinib...
August 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29662541/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-in-adults-following-prior-vascular-endothelial-growth-factor-targeted-therapy-clinical-trial-evidence-and-experience
#18
REVIEW
Susanne Osanto, Tom van der Hulle
Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. Chronic treatment with vascular endothelial growth factor receptor (VEGFR)-targeting sunitinib upregulates MET and AXL in RCC, indicating that cabozantinib may be particularly effective in patients with advanced RCC whose disease progressed on prior VEGFR-targeted treatment...
March 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29661736/loss-of-pd-l1-sp-142-expression-characterizes-renal-vein-tumor-thrombus-microenvironment-in-clear-cell-renal-cell-carcinoma
#19
José I López, Rafael Pulido, Charles H Lawrie, Javier C Angulo
Immunotherapy is a promising tool in the treatment of patients with advancer renal cancer, in particular the blockage of immune checkpoint inhibitors. Clear cell renal cell carcinoma is an example of heterogeneous neoplasm and this particular characteristic is responsible of many therapeutic failures so far. Since variations in the local microenvironment across a tumor may conditionate the effect of this new therapy, a deeper knowledge of this issue seems advisable for any treatment success. We have analyzed the PD-L1 (SP142) expression in three different areas in the tumor and in two areas in the renal vein/caval thrombi in 39 advanced clear cell renal cell carcinomas to determine the extent and potential clinical significance of this regional variability...
March 24, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29661727/investigation-of-the-relationship-of-epstein-barr-virus-with-in-situ-hybridization-in-renal-cell-carcinomas
#20
Serap Karaarslan, Nazime Şen
No abstract text is available yet for this article.
February 20, 2018: Annals of Diagnostic Pathology
keyword
keyword
21147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"